Article: Other News To Note.

o Acusphere Inc., of Watertown, Mass., entered an agreement to lease commercial manufacturing space in Tewksbury, Mass. The specialty pharmaceutical company plans to develop the facility to meet its anticipated initial commercial production needs for AI-700, an ultrasound contrast agent in Phase III trials for the detection of coronary heart disease.

o ArQule Inc., of Woburn, Mass., said a Phase I study of ARQ 501 as monotherapy continues to enroll patients. The drug has been well tolerated, the company said, and dose escalation will continue to identify the maximum tolerated dose. In the latter part of the year, a new Phase Ib/II study combining ARQ 501 with ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!